NFl is a common genetic disorder characterised by multiple neurofibromas, cafe au lait spots, axillary freckling, and pigmented iris hamartomas (Lisch nodules). Affected subjects often exhibit additional complications including various kinds of osseous lesions, optic glioma, learning disabilities, and malignancy.' NF1, an autosomal dominant disorder, is notable for its variable expressivity, with clinical presentations that may vary from mild to severe within a single family. The NFI gene exhibits a high mutation rate, and approximately 50% of index cases represent new mutations. ' Because of the large size of the NFl gene, traditional methods of mutation screening have tended to focus on one portion of the gene at a time rather than on the entire coding region. Since disease causing mutations are dispersed throughout the gene, these studies have detected mutations in a relatively small proportion of subjects. For example, one study used chemical mismatch cleavage to screen 70% of the coding region in 25 NF1 patients and identified potentially disease causing mutations in 28% of subjects.3 Other studies focused on smaller regions of the gene and detected mutations in a correspondingly smaller fraction of subjects.9 Other than protein truncation testing, the only reported method developed to screen the entire coding region used long RT-PCR to amplify the entire 8.5 kb open reading frame and full length RT-PCR products were digested with restriction enzymes. 0 By this method, mutations associated with deletion or insertion within the mRNA altered the size of the RT-PCR product and the restriction digest improved the resolution with which size changes could be detected. Still, the authors predicted the method to yield positive results in only 30% of previously reported NFl mutations.
Compared to other methods, the protein truncation test (PTT) provides improved efficiency in detecting NFl mutations. " First developed for use in Duchenne muscular dystrophy (DMD)" and familial adenomatous polyposis (APC),'3 PTT has been applied to mutation screening in numerous genes 1l8 including NFl.1 19 20 A primary advantage of the method is its ability to screen an entire coding region for any type of sequence alteration that affects the size of the encoded protein. This is accomplished by using one or more amplified segments of the gene as substrate for coupled in vitro transcription and translation. Mutations causing premature termination of translation within a given segment yield protein products of less than the expected size. Such truncating mutations are common in NFl, where approximately 80% of fully characterised mutations detected by methods other than PT are predicted to lead to severe truncation of neurofibromin.' In the current study, mutations were identified in 1 1 of the 15 patients screened (73%), which is the highest rate of mutation detection reported in a study of typical NFl patients.
Subjects, material, and methods
SUBJECTS
All study participants were recruited from the clinic population of the University of Tennessee, Memphis NF Clinic according to an IRB 29 and 30.26 RT-PCR products were subjected to coupled transcription and translation followed by protein gel electrophoresis. The normal protein banding pattern for each segment consisted of a predominant band corresponding to the expected full length product (range of approximately 38-43 kDa for different segments) plus a predictable pattern of background bands ( fig  2) . As expected for subjects heterozygous for a dominant disorder, all specimens yielded full length product for each segment. In addition, .n _n .z group.bmj.com on April 1, 2017 -Published by http://jmg.bmj.com/ Downloaded from Four of the five aberrant transcripts (all except 61-586del) introduced stop codons just downstream of exon 4a. These four were predicted to encode protein products of similar size (approximately 19 kDa), which was in good agreement with the observed truncated protein band of approximately 18 kDa. Although the 61-586del transcript also altered the reading frame, the encoded peptide of 28 amino acids (3.4 kDa) would be below the resolving power of the gel system and was not observed. Interestingly, the shortened band of 0.5 kb seen by RT-PCR ( fig 1A) corresponded in size with 61-586del, whereas the other aberrantly spliced RT-PCR products were only marginally visible by agarose gel electrophoresis. All abnormalities observed in this patient predicted severe protein truncation and probably complete loss of function in vivo.
Discussion
Mutation screening in NFl has been hindered by the large size of the gene and by the random distribution of disease causing mutations. We used a protein truncation test to screen the entire coding region in 15 NF1 patients and detected 10 different mutations in 11 patients. By reducing the sizes of the segments screened from approximately 2 kb'1 to approximately 1.1 kb, we achieved consistently high yields of RT-PCR product, which were associated with good resolution and low background on protein gels. The newly reported mutations were distributed throughout the gene and included nine truncating mutations (seven frameshift and two nonsense) and one in frame deletion. Four splice errors were detected and all involved exon skipping. The current study adds to the growing body of reports showing the usefulness of PTT for mutation screening in disorders where disease causing mutations are heterogeneous and loss of function mutations are common. PROTEIN fail to amplify, the observed product represents only the normal allele rather than both gene copies. Since PTT is not quantitative, an apparently normal result is obtained. Segment specific amplification failure may occur because a mutation destroys one or more primer annealing sites or because of the presence of a large insertion that increases the size of a particular segment beyond the length that can be amplified. The overlap between adjacent segments provides partial protection against false negatives caused by amplification failure, since a mutation that destroys one priming site should be picked up as a truncating event within the overlapping segment. Two mutations reported here illustrate successful use of this safeguard. The mutation 1393-1527del skips exon lOb, which contains the forward priming site for segment 3, and 6580-6641del skips exon 35, which contains the forward priming site for segment 9. Each mutation was detected as a result of truncation within the respective upstream segment (2 or 8). However, a somewhat larger deletion, encompassing the region of overlap between two adjacent segments, would be missed since one primer annealing site from each segment would be destroyed.'" Truncating mutations may also be missed if the size of the truncated product falls outside the resolving ability of the protein gel system (for example, 61-586del in .
No accurate estimate is available of the relative contributions of various factors in limiting the sensitivity of PTT. Of particular interest is the percentage of truncating mutations that are missed. In one review,2 80% of fully characterised mutations detected by methods other than PTT were associated with a significant change in protein size. In other studies using PTT for mutation screening in NF1, detection rates were 67% (14 mutations in 21 subjects)," 54% (seven mutations in 13 subjects),20 and 44% (eight mutations in 18 subjects).'" In combination with the present study, PTT has identified 40 NFl mutations in 67 affected subjects (60%). Thus, an approximation of the sensitivity of PTT in detecting truncating mutations is 75% (60/80). Interestingly, the study with the lowest detection rate'9 evaluated children with myeloid malignancies and used affected tissue (bone marrow) for mutation screening in the majority of cases. As suggested by those authors, destabilisation of RNA may be a significant factor limiting the efficiency of PTT.
MUTATIONS
The mutations described here are consistent with previous reports in failing to Interestingly, partial iris heterochromia was observed in two unrelated subjects (96-62, . Both carried truncating mutations caused by exon skipping, but the mutations were at opposite ends of the gene (exons 4c and 35, respectively), and no common mechanism was apparent. Although heterochromia of the iris has been reported in association with NF 148 and may be another manifestation of NF1 associated neurocristopathy, its significance is unknown.
A primary goal of mutation screening, correlations between genotype and disease phenotype, continues to be difficult in NFl. In addition to efficient methods of mutation identification, more studies of gene function, protein function, and the genetic basis of disease progression are needed to understand the pathogenesis of this complex disease.
Note added in proof The 31 bp cDNA insertion observed in patient 95-15 ( fig 4B) is from intron 4a (gb/ AC004222/AC004222). Cryptic splicing of this sequence has been observed by others in some NF1 tumours (M R Wallace, unpublished results).
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